Minerva Cardiology and Angiology, published by EDIZIONI MINERVA MEDICA, is a prominent journal in the field of cardiology and cardiovascular medicine, with an ISSN of 2724-5683 and E-ISSN of 2724-5772. Established in 2021, this journal aims to foster the dissemination of cutting-edge research, clinical practice guidelines, and innovative methodologies relevant to cardiovascular health. As of 2023, it holds a commendable Q3 quartile rank in its category, reflecting its growing influence within the scientific community. The journal is indexed in Scopus, where it ranks #221 out of 387 in its field, placing it in the 43rd percentile overall. Although it currently does not offer Open Access options, articles published in Minerva Cardiology and Angiology contribute significantly to ongoing discussions and advancements in heart and vascular health. The journal serves as an invaluable resource for researchers, healthcare professionals, and students seeking to stay informed on the latest developments in cardiology.

Cardiology in Review, published by Lippincott Williams & Wilkins, is a prominent journal focused on advancing the field of cardiology and cardiovascular medicine. With a history of publication spanning from 1995 to 2024, the journal serves as an essential resource for researchers, healthcare professionals, and students alike, offering in-depth reviews and analyses on the latest developments, clinical practices, and research findings in cardiology. Despite being a traditional print journal, it maintains a commendable Q2 ranking in both cardiology and miscellaneous medicine categories as of 2023, reflecting its influence and rigor in the academic community, with a Scopus rank of #132 out of 387 in its field, placing it in the 66th percentile. The journal aims to bridge the gap between clinical practice and emerging research, promoting a deeper understanding and integration of innovative strategies in cardiovascular care. With its commitment to high-quality scholarship, Cardiology in Review remains a vital conduit for knowledge and dialogue within the evolving landscape of cardiovascular health.

International Journal of Cardiology Cardiovascular Risk and Prevention is a distinguished Open Access journal published by ELSEVIER, dedicated to advancing research in the realms of cardiology and cardiovascular medicine. With an ISSN of 2772-4875 and based in the Netherlands, this journal has rapidly established itself as a critical resource for academics and practitioners since its inception in 2021. The journal currently holds a respectable impact factor and occupies the Q2 quartile in both Cardiology and Cardiovascular Medicine and Internal Medicine categories, reflecting its commitment to sharing high-quality research. Researchers can take advantage of its open-access model, ensuring that cutting-edge findings are freely available to a global audience. The journal not only covers innovative studies on cardiovascular risk factors and prevention strategies but also aims to facilitate interdisciplinary collaboration. With an ongoing trajectory from 2021 to 2024, the International Journal of Cardiology Cardiovascular Risk and Prevention is poised to remain a pivotal platform for dialogue and discovery in the evolving landscape of cardiovascular health.

COPD - Journal of Chronic Obstructive Pulmonary Disease is a premier peer-reviewed journal published by Taylor & Francis Inc. that focuses on the latest advancements in the understanding, diagnosis, and treatment of chronic obstructive pulmonary disease (COPD). As an Open Access journal since 2022, it enhances availability and dissemination of groundbreaking research, allowing researchers, healthcare professionals, and students to access vital information without barriers. The journal has established itself as a significant resource in pulmonary and respiratory medicine, boasting a commendable Q2 ranking in both medicine and specialty areas as of 2023, with an impressive Scopus rank of 66 out of 155. By bridging the gap between scientific exploration and clinical application, COPD aims to foster innovative approaches to managing this prevalent condition, making it an essential publication for those dedicated to improving patient care and advancing respiratory health.

Arterial Hypertension is a dedicated Open Access journal published by VIA MEDICA, with the ISSN 2449-6170 and E-ISSN 2449-6162, focusing on the multidisciplinary field of cardiology, endocrinology, and internal medicine. Established in Poland, this journal has been providing researchers and healthcare professionals with accessible, high-quality content since its inception in 1999. With a commitment to advancing knowledge in the management and treatment of arterial hypertension, it publishes significant research findings, clinical trials, and reviews that contribute to improved health outcomes. Though classified in Q4 across various relevant categories, the continuous improvement in its content ensures its relevance in an evolving medical landscape. Designed to facilitate collaboration and innovation, Arterial Hypertension serves as a crucial resource for anyone invested in cardiovascular health, encouraging open dialogue and dissemination of vital research within the scientific community.

HYPERTENSION, published by Lippincott Williams & Wilkins, is a preeminent journal in the field of cardiovascular medicine, focusing on the latest research, therapies, and clinical practices related to hypertension and its associated disorders. With a distinguished Q1 ranking in Internal Medicine and a commendable Scopus rank of #12 out of 167 in its category, it occupies a vital position within the academic community, appealing to researchers, clinicians, and educators alike. The journal has been disseminating impactful findings since 1979 and continues to influence the discourse on hypertension through rigorous peer-reviewed articles, reviews, and studies designed to elevate understanding and treatment of this prevalent condition. HYPERTENSION remains an essential resource for professionals keen on advancing their knowledge in this critical area of medicine, fostering innovations that ultimately improve patient care.

The International Journal of Chronic Obstructive Pulmonary Disease, published by DOVE MEDICAL PRESS LTD, serves as a premier platform for researchers and professionals involved in the study and management of COPD. Established in 2006 and transitioning to an Open Access model in 2009, this journal has quickly gained a reputable standing in various impactful categories, achieving Q1 rankings in Health Policy, Medicine (Miscellaneous), and Public Health, among others. With a focus on disseminating high-quality research, the journal is pivotal for addressing global public health challenges associated with chronic obstructive pulmonary disease. The journal's dedication to open access ensures that vital information reaches a broader audience, fostering advancements in research and clinical practice. By maintaining rigorous peer-review standards and a commitment to the advancement of understanding in COPD, the journal attracts significant contributions from scientists and practitioners worldwide, making it an invaluable resource for ongoing education and research development in this critical area.

BLOOD PRESSURE is a distinguished journal published by Taylor & Francis Ltd in the field of cardiology and internal medicine, with an ISSN of 0803-7051 and E-ISSN of 1651-1999. Since its inception in 1992, it has become a vital source of research and clinical information, dedicated to advancing our understanding of blood pressure-related health issues. With a notable categorization of Q3 in Cardiology and Cardiovascular Medicine and Q2 in Internal Medicine as of 2023, this journal exemplifies a commitment to evidence-based findings that impact clinical practice and patient care. The journal facilitates a platform for original research, reviews, and case studies, aiming to bridge the gap between researchers and practitioners. Although it does not currently offer open access, BLOOD PRESSURE remains an essential resource for professionals and students alike, striving to enhance health outcomes through dedication to innovative cardiovascular research.

JOURNAL OF NEPHROLOGY is a premier academic journal dedicated to the field of nephrology, published by Springer Heidelberg. With its ISSN 1121-8428 and E-ISSN 1724-6059, this journal serves as a dynamic platform for disseminating high-quality research and groundbreaking findings in kidney health and disease. Since its inception in 1989, it has established itself as a vital resource for professionals, researchers, and students, consistently ranking in the top quartile (Q1) of nephrology journals and securing an impressive Scopus rank of #19 out of 81, placing it in the 77th percentile. Although it operates under a subscription model, the journal fosters an inclusive academic environment where critical discussions and innovative approaches to nephrological challenges are encouraged. With a commitment to advancing knowledge and practice in nephrology, JOURNAL OF NEPHROLOGY remains an essential resource for anyone who seeks to stay at the forefront of kidney research and clinical care.

The International Journal of Hypertension, published by HINDAWI LTD, is a pivotal open-access journal dedicated to advancing knowledge in the field of hypertension and cardiovascular health. Since its inception in 2010, the journal has provided a vital platform for researchers, clinicians, and students to disseminate innovative findings and comprehensive reviews spanning various aspects of hypertension management, pathophysiology, and epidemiology. Residing in Q3 of the Internal Medicine category and ranked 75 out of 167 in the Scopus rankings, it reflects a commitment to quality and relevance in medical research. With a global reach, the journal aims to foster collaboration and knowledge exchange, contributing significantly to the scientific community's efforts to combat hypertension-related health issues. Accessible since 2010, this journal exemplifies the principles of open science, ensuring that critical research is available to all stakeholders in the field.